Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

February

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes...

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

Studies evaluating methods to overcome two major challenges in treating patients with liver and...

14

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive...

22

TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors

PERIO-1 and PERIO-2 studies evaluating integration of SD-101 and PEDD administration DENVER and CHICAGO,...

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

Studying the delivery of SD-101 via pressure-enabled drug delivery in adults with hepatocellular carcinoma...

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver...

10

TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisory Boards

Additions will support company focus to overcome liver and pancreatic cancer treatment barriers and...

20

TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus

Three-year program aims to advance research on innovative immuno-oncology treatments for patients with liver...

6

Global Liver Institute and TriSalus Life Sciences Launch New Liver Cancer Resource Hub

“Liver Central” is a comprehensive online guide for liver cancer researchers, clinicians and patients...

6

TriSalus Life Sciences Appoints Sean Murphy to Board of Directors

Industry expert brings decades of experience commercializing biopharmaceutical, medical device and diagnostic products DENVER,...

14

TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists

Regional Delivery of Oligodeoxynucleotides (ODN2395) Showed Activation of Toll-Like Receptor Agonist in Mice Ineffective...

9

TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System

Transitional Pass Through Payment (TPT) Facilitates Patient Access to New and Innovative Products That...

Recent developments

News

February

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

December

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

November

14

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

June

22

TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors

May

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

April

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

February

10

TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisory Boards

January

20

TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus

January

6

Global Liver Institute and TriSalus Life Sciences Launch New Liver Cancer Resource Hub

October

6

TriSalus Life Sciences Appoints Sean Murphy to Board of Directors

April

14

TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists

February

9

TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System